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Abstract

NIH-PA Author Manuscript

The principal role of the placenta is the maintenance of pregnancy and promotion of fetal growth
and viability. The use of transgenic rodents has greatly enhanced our understanding of placental
development and function. However, embryonic lethality is often a confounding variable in
determining whether a genetic modification adversely affected placental development. In these
cases, it is beneficial to specifically manipulate the placental genome. The purpose of this review
is to summarize available methodologies for specific genetic modification of the rodent placenta.
By restricting genetic alterations to the trophoblast lineage, it is possible to gain a deeper
understanding of placental development that perhaps will lead to gene-targeted therapies to rescue
irregular placentation in transgenic animals or in women at high-risk for placenta-associated
pregnancy complications.
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1. Introduction
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The placenta functions to facilitate the exchange of molecules between maternal and fetal
circulations and to provide endocrinological and immunological support for pregnancy.
Aberrant placental development is implicated in many pregnancy complications, impacting
both fetal development and maternal health [1]. Therefore, gaining a deeper understanding
of placental development, both normal and irregular, is of significant clinical importance.
The placenta contains anatomically distinct zones wherein architecture and function is
dependent on the progressive differentiation of trophoblast cells. Trophoblast cells comprise
a heterogeneous population of cells derived from progenitor trophoblast stem (TS) cells [2].
Trophectoderm, the eventual source of TS cells, is the first lineage-committed cell-type to
appear during embryogenesis, emerging as polarized cells segregated to the periphery of the
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blastocyst. The remaining internal cells form an inner cell mass from which two populations
of lineage-committed cells have been derived: extraembryonic endoderm (XEN) and
embryonic stem (ES) cells [3]. While XEN and ES cells are fated to form yolk sac endoderm
and all germ layers of the fetus, respectively, TS cells undergo a multilineage differentiation
pathway resulting in distinct subpopulations of specialized trophoblast cells.
Characterization of these trophoblast subtypes has revealed unique ontogeny, morphology,
and function [4].
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In rodents, the placenta can be divided into two regions: the junctional zone and the
labyrinth zone. The junctional zone is an active endocrinological and invasive tissue situated
at the uterine-trophoblastic border, and is comprised of trophoblast giant cells,
spongiotrophoblast cells, and glycogen cells. Later in gestation, the invasive trophoblast
lineage develops within the junctional zone, and actively migrates into the maternal decidua
[5]. The labyrinth zone is the site at which transfer of nutrients between maternal and fetal
circulations occurs, and is comprised of mesenchymal villous structures bordered by fused
syncytiotrophoblast and a discontinuous cytotrophoblast layer bathing in maternal blood.
Although some aspects of placentation differ between humans and rodents, there are
fundamental similarities between these species in terms of placental structure, development,
and function [6–8]. Thus, the capacity to genetically modify rodent trophoblast
subpopulations, or the placenta in general, provides valuable information on processes
integral for placental development and function.
The purpose of this review is to discuss available methodologies for genetic modification of
the rodent placenta. Whole-body gene manipulation has enabled researchers to identify roles
for genes in many tissues; however placental function is inherently vital for fetal viability;
thus embryonic lethality is often a confounding variable in deciphering whether a genetic
modification affected placental or fetal development. By restricting the genetic manipulation
to the placenta, it is possible to more clearly define the effects on placental development and
function. Techniques for genetic modification of the placenta, which are represented
schematically in Figure 1, will be categorized as follows: i) transgene expression using
trophoblast-specific promoters; ii) cell-based modulation of placental gene expression, and
iii) viral strategies for genetic manipulation of the placenta.

2. Trophoblast-specific gene promoter mediated manipulations
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Genetic modulation of the placenta eliminates the ambiguity associated with embryonic
lethality in whole-body transgenics. This approach is made feasible by insertion of genes
downstream of promoters that are active in specific trophoblast subpopulations. Inserted
genes are then expressed only in trophoblast subtypes containing the active promoters,
where they facilitate gain-of-function or loss-of-function effects. The critical limitation for
this strategy is the identification of gene promoters that are active with relative exclusivity in
trophoblast cell-types. Thus far, several such genes have been recognized (Table 1). In some
cases, such as with the purine-catabolizing enzyme adenine deaminase (ADA), the gene is
active in all trophoblast derivatives [9]. Trophoblast ADA expression, which commences at
mid-gestation and increases until term, protects the embryo from purine cytotoxicity. Using
transgenic mice, it was found that a 770-bp region situated 5.4-kb upstream of the ADA
transcription start site is sufficient to drive expression of a reporter construct exclusively in
the mouse placenta [10]. Therefore, transgene insertion downstream of the ADA promoter
may be a putative means of expressing transgenes in all trophoblast derivatives.
Many genes exhibit a temporal or cell-specific expression pattern in the placenta and may be
useful for targeting trophoblast subpopulations during certain gestational periods. Such is
the case with the rodent prolactin (PRL) superfamily. The genes that encode these proteins
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are organized contiguously on the same chromosome. Each gene shows a characteristic
temporal and trophoblast cell-specific expression pattern [11]. Although the promoter motifs
that drive in vivo expression of most PRL family members are unknown, the endogenous
placental lactogen-II (PL-II; Prl3b1) promoter, which is activated in rodent trophoblast
giant cells and, at least in mice, spongiotrophoblast cells during the latter half of pregnancy,
has been effectively used to target gene expression to the mouse placenta [12,13]. In
particular, a region spanning −2019 to −1340 bp upstream of the PL-II transcription start
site drove reporter expression specifically in the placenta of transgenic mice [14]. The
promoter regions of several other PRL family members, including PL-I/Prl3d1 [15–17],
PLP-A/Prl4a1 [18], dPRP/Prl8a2 [19], and PLP-Cv/Prl8a3 [20], have been characterized in
vitro using the Rcho-1 rat trophoblast cell line, but the efficiency of these promoter regions
in driving trophoblast-specific gene expression in vivo is unknown. Characterization of the
promoter regions of these and other PRL family genes would be invaluable in targeting
transgenes to specific trophoblast subpopulations at precise gestational periods.
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The promoter regions of other genes that are expressed in trophoblast cells have been used
to promote transgene expression within the placenta in vivo. One example is the promoter
region for Tpbpa (4311), which exhibits restricted expression within a subset of cells of the
ectoplacental cone commencing at gestational day 7.5 in mice, and subsequently in
trophoblast cells comprising the junctional zone for the duration of pregnancy. Promoterreporter analyses identified a 340-bp sequence approximately 3740-bp upstream of the
Tpbpa transcription start site required for trophoblast-specific expression [21]. This
promoter region has been used to drive expression of Cre-recombinase and green
fluorescent protein (GFP) exclusively in junctional zone trophoblast cells [22],
demonstrating its efficacy for directing transgene expression in this region of the placenta.
The promoter regions of other genes that have been characterized to drive in vivo transgene
expression in the placenta include renin (expressed in trophoblast giant cells) [23], growth
hormone-releasing hormone (expressed in junctional zone trophoblast cells) [24], and
eomesodermin (expressed in early trophoblast progenitors) [25]. However, transgene
expression in tissues other than trophoblast was also noted for each gene, so the promoter
regions for these genes may not yet be ideal for directing placenta-specific transgenesis.

NIH-PA Author Manuscript

The promoter regions of the genes discussed above have been used to drive transgene
expression within the junctional zone. Modulation of promoters active in rodent labyrinth
zone syncytiotrophoblast has been less successful, although characterization of the promoter
regions of the recently identified Syncytin genes [26], may be a possible means to drive
transgenes exclusively in rodent labyrinth. Regardless, the most effective means thus far for
genetic manipulation of rodent syncytiotrophoblast has been to generate animals expressing
transgenes driven by promoter regions active in human syncytiotrophoblast. For instance,
the upstream locus control region (LCR) of human chorionic somatomammotropin (hCS), a
member of the human growth hormone (hGH) gene cluster activated exclusively in human
syncytiotrophoblast, is effective in driving transgene expression specifically in rodent
syncytiotrophoblast despite the lack of a rodent ortholog for this gene [27–29]. Therefore,
the necessary transcriptional machinery required to activate the LCR and upstream promoter
sequences for hCS is present in mouse syncytiotrophoblast. Likewise, the CYP19
(aromatase) gene, which facilitates the conversion of androgens to estrogens, is expressed in
human syncytiotrophoblast but not in rodent placenta. Using reporter constructs driven by
the CYP19 promoter, Kamat et al. have observed that 501-bp upstream of CYP19 exon I.1,
an exon encoding the 5′-untranslated region of CYP19 transcripts exclusively transcribed in
human placenta, is sufficient to induce reporter expression in mouse syncytiotrophoblast
[30,31]. Another group has used this 501-bp hCYP19 promoter to drive expression of Cre
recombinase in mouse placenta. However, in this case the transgene was detected in all
trophoblast derivatives rather than just syncytiotrophoblast [32]. Regardless, the promoter
Placenta. Author manuscript; available in PMC 2012 March 1.
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regions that drive expression of hCS and CYP19 in human syncytiotrophoblast are effective
means of driving transgene expression specifically in the rodent placenta.
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3. Transplantation of cells to modulate placental gene expression and
function
Transplantation of cells is an effective means to introduce genetically modified cells into a
placenta. This methodology involves combining two or more populations of cells from
different genetic backgrounds to produce a conceptus comprised of several populations of
genetically-distinct cells. Two approaches have been used to accomplish this feat:
intraplacental engraftment and chimerism.
3.1. Intraplacental engraftment
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Engraftment of cells to the placenta was a technique established by Senut et al. [33]. In their
study, cultured rat or human cells genetically modified to express either LacZ or human
growth hormone (hGH) were injected into rat placentas. Following injection, cells
successfully engrafted to the placenta as evidenced by beta-galactosidase activity and the
detection of hGH in placental and fetal circulations [33]. Therefore, this methodology may
be an effective means to continuously deliver biologically active molecules in utero. The
primary limitation of this procedure was the injurious nature of injection, which dramatically
reduced fetal viability when performed earlier than embryonic day (E)15 in rats. In addition,
engraftment of foreign cells was associated with instigation of an inflammatory response,
which could affect the delicate immune balance required for successful pregnancy.
Regardless, refinements may allow for this technique to be an effective means for
experimentally manipulating the placenta.
3.2. Chimerism
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Chimerism is a technique whereby embryos from different genetic backgrounds are
aggregated together to form a single embryo that has two or more populations of genetically
distinct cells. Initially this methodology was restricted to the aggregation of early mouse
embryos, resulting in chimerism in both embryonic and extraembryonic (derivatives of
trophectoderm and primitive endoderm) lineages. Advances in the stability and culture of ES
cells have facilitated an alternative source of embryonic cells in chimera generation. Despite
the technically arduous nature of these procedures, chimeras have been an invaluable tool in
the production of mutant animals. In keeping with the placenta-centric theme of this review,
we will focus only on the use of chimeras for deciphering the effects of genetic
modifications on extraembryonic lineage development. For a detailed description of chimera
generation and applications, see Tam and Rossant [34].
Since ES cells differentiate into embryonic structures and are incapable of contributing to
primitive endoderm or trophectoderm derivatives, ES cell-embryo chimeras are a useful tool
to delineate lineage-specific consequences of genetic mutations [35]. Determining the effect
of a mutation on embryonic versus extraembryonic tissues then depends on the source of the
genetic modification i.e. whether the mutation is carried by ES cells or the embryo.
However, regardless of the source the genetic constitution of the embryo is a mixture of
mutant and wild-type cells, making results obtained by this technique somewhat
inconclusive.
To more specifically determine the impact of genetic modifications on embryonic versus
extraembryonic tissues, an amendment to conventional chimera generation can be performed
to exclusively direct cells towards extraembryonic development. This adjustment entails
electrofusion of a two-cell stage embryo, resulting in a single cell with twice the normal
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number of chromosomes, i.e. tetraploid. Generation of a chimera using a pre-implantation
tetraploid embryo aggregated with diploid ES cells results in lineage exclusivity, with
tetraploid cells contributing wholly to the formation of extraembryonic structures and ES
cells restricted to producing embryonic entities [36].
Tetraploid complementation has been used to decipher whether embryonic lethality as a
result of gene targeting is due to deficiencies in embryonic or extraembryonic structures. For
example, rescue of embryonic lethality in SOCS3-deficient embryos, which normally die in
utero, was facilitated by aggregation of SOCS3-deficient embryos with tetraploid wild-type
embryos [37]. Unfortunately, tetraploid complementation does not allow for discerning
whether failure of extraembryonic tissue development is due to defects in trophoblastic or
primitive endodermal derivatives. To address this issue, Takahashi et al. performed a novel
chimeric analysis by microinjecting wild-type TS cells into the blastocoel of SOCS3defective embryos [38]. These injected TS cells successfully contributed to the formation of
the placenta, resulting in partial rescue of embryonic lethality. Although these authors found
this methodology to be less effective than tetraploid complementation, future refinements to
this technique could provide an effective means to rescue lethalities due to placental
insufficiency and also to assess the competencies of TS cells possessing specific mutations.

4. Viral delivery strategies for genetic manipulation of the placenta
NIH-PA Author Manuscript

An alternative approach to produce genetic modification of the placenta is to directly
introduce novel genetic material to the organ itself. One of the most effective means to
accomplish this is to use viral gene delivery. Recombinant viruses have successfully been
used in vitro as gene delivery vehicles to isolated cells or tissues, but in vivo studies have
been somewhat slower to adopt this technology because of the potential for carcinogenicity,
immunogenicity, and inconsistency of transgene expression [39]. However, due to the
transitory, extraembryonic nature of the placenta, this organ could be an ideal future
candidate for viral-mediated gene delivery in animal models and in patients who exhibit a
high risk for some pregnancy complications. For research purposes, the most commonly
used vectors for mediation of gene delivery have been adenoviruses and retroviruses.
4.1. Adenoviruses
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Adenoviruses are non-enveloped icosahedral viruses composed of a nucleocapsid and a
double-stranded linear DNA genome. They are capable of transducing both dividing and
non-dividing cells and confer high levels of transgene expression. Once inside the host cell,
adenoviral DNA enters the nucleus but is not integrated into the genetic material of the host;
hence it is not transmitted to daughter cells. Moreover, adenoviral particles are recognized
by the innate immune system, resulting in efficient clearance of virus. Therefore, because
adenoviruses are not transmitted to daughter cells and are efficiently cleared by the immune
system, recombinant adenoviral vectors are useful options for gene delivery to a slowreplicating population of cells for a defined period of time.
Administration of recombinant adenoviral vectors to pregnant mice, rats, rabbits, and sheep
has been used to confer transgene expression in both the fetus and placenta. Although
systemic administration of these vectors is effective in transducing fetal and placental cells,
in utero inoculation is more effective in its specificity and infectivity for the fetal-placental
unit [40]. In particular, direct inoculation of the placenta with recombinant adenovirus has
been successfully used to alter gene expression specifically in this organ. For example, Xing
et al. used an intra-placental injection of recombinant adenovirus to pregnant rats on E14 to
induce expression of the human glucose transporter GLUT3 [40]. A later study in pregnant
mice used intra-placental injection of adenovirus expressing various growth factor
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transgenes to determine the effect of these mitogens on late gestation placental and fetal
growth [41].

NIH-PA Author Manuscript

Despite the promising foundations provided by these studies, adenoviral-mediated gene
delivery to the placenta exhibits several limitations. First, adenovirus infection is capable of
eliciting an immune response, and this could have repercussions for the delicate immune
balance required for pregnancy. Second, efficient adenoviral infection and transgene
expression is restricted to a narrow time-window. In mice and rats, researchers have been
limited to injecting mid- to late-gestation placentas, partly because of the lack of adenoviral
transmittance to daughter cells and because intra-placental injection is an injurious technique
that may reduce fetal viability if performed earlier than E13.5. Others also noted that if
injection of adenovirus was delayed until later than E16.5 in rat pregnancy, transgene
expression in the placenta was diminished, indicating resistance to infection [40]. Despite
these limitations, the transient nature of adenovirus infection, failure to stably integrate into
the host genome, and high levels of transgene expression make adenovirus-mediated gene
delivery a good candidate for some types of placental research.
4.2. Retroviruses
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Retroviruses are enveloped viruses containing an RNA genome and proteins including
reverse transcriptase. Once inside a host cell, reverse transcriptase catalyzes the conversion
of the viral RNA genome to complementary DNA, which then stably integrates into the
genetic material of the host cell and is transmitted to cell progeny. Although most
retroviruses are only capable of low-level transgene expression and infection is restricted to
dividing cells, a subset of retroviruses - lentiviruses - can transduce dividing or non-dividing
cells and is less prone to transgene silencing than conventional retroviruses [42]. Thus,
lentivirus-based vectors are currently the preferred choice for retroviral-mediated transgene
delivery.
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Due to the stable transmittance of lentiviral infection to cell progeny, researchers have
achieved extensive transgene expression at later stages of development in embryonic and
extraembryonic tissues after exposure of early embryos to lentiviral vectors. Further
research using these vectors was able to accomplish more specific extraembryonic transgene
expression by exploiting the physical properties of blastocysts. In a landmark study using
rhesus monkey blastocysts, Wolfgang et al. showed that transgene delivery could be
restricted to trophectoderm and primitive endoderm derivatives by microinjecting lentiviral
vectors into the blastocoel [43]. More recent studies in mice have achieved even greater
specificity for trophectoderm and its derivatives by simply immersing zona pellucida-free
blastocysts in medium containing lentivirus. Due to the peripheral positioning of the
trophectoderm, these cells were readily transduced by lentivirus, but inner cells were
shielded from infection by the epithelial tight junctions of the trophectoderm [44,45].
Specificity for the trophoblast lineage and efficiency of infection was confirmed by
transferring blastocysts infected with lentivirus carrying reporter constructs to
pseudopregnant dams, and observing reporter expression later in pregnancy exclusively in
the placenta. Since these initial studies were performed, transgene expression via blastocyst
transduction with lentiviral vectors has been effectively performed in mice [45], rats [46],
and sheep [47], indicating that this is a feasible methodology for altering gene expression in
the placenta in many species.
Lentivirus infection of blastocysts has been used as a means to deliver transgenes to the
placenta resulting in gain-of-function or loss-of-function phenotypes. As an example of the
former, in Ets2−/− or Mapk14−/− mice that both die in utero as a result of deficient
placentation, reversal of embryonic lethality was achieved following blastocyst transduction
by lentivirus carrying functional transgenes for Ets2 or Mapk14, respectively [44]. Loss-ofPlacenta. Author manuscript; available in PMC 2012 March 1.
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function phenotypes have been observed following lentiviral delivery of short hairpin-RNA
(shRNA) specific for target genes. Although to-date transgenic shRNA-mediated gene
silencing in rodents has targeted reporter genes [45,46], Purcell et al. have used this
methodology to decrease Proline-Rich 15 gene expression in sheep trophectoderm in order
to determine the role of this protein in conceptus elongation [47]. Thus, lentiviral delivery
should be an effective strategy for genetically manipulating the trophoblast lineage from any
mammalian species.
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An alternative and more robust means for loss-of-function phenotypes is through lentiviralmediated delivery of transgenes encoding Cre recombinase in animals expressing a targeted
floxed gene. This methodology was first established by Georgiades et al., who infected
trophectoderm with a viral vector encoding Cre recombinase. Following genomic
integration of Cre recombinase, floxed reporter genes were excised as indicated by
alterations in the expression of the appropriate reporters [45]. Further studies by Morioka et
al. used lentiviral vectors for delivery of Cre recombinase to trophectoderm in order to
excise floxed Ets2 in the host genome [48]. The obvious advantage of this technique is that a
placenta-specific promoter is not required to drive expression of Cre recombinase, thereby
increasing the feasibility of generating placenta-specific knockouts using animals containing
a desired floxed gene. The limitations of this latter research approach is the need to
manipulate endogenous genes via homologous recombination in a pluripotent cell
population such as ES cells, which to date is only a routine procedure in mice.

5. Overview
In this review, we summarized currently established techniques for specific genetic
modification of the rodent placenta. Rodent transgenesis has greatly facilitated scientific
advancement in many fields, but has been of limited use in understanding placental biology
due to embryonic lethality. However, the incorporation of new research strategies has
enabled researchers to decipher the effect of a genetic modification on placental
development and function. Given that placental irregularities are associated with various
pregnancy complications, a further understanding of the processes governing placental
development and function is clinically important. Moreover, refinement of these techniques
may eventually allow for genetic modification of the human placenta to facilitate pregnancy
success in high-risk cases of pregnancy complications due to placental irregularities.
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Figure 1. Schematic representation of techniques to facilitate genetic modification of the rodent
placenta

Unboxed flow chart in middle of diagram depicts progression from zygote through to mature
conceptus. A) Pronuclear injection of transgene-containing DNA driven by placenta-specific
promoter. Note that only the mature placenta expresses the transgene (green). B) Generating
a chimera by aggregating an early embryo and transgenic ES cells. Please observe that ES
cells are only capable of contributing to the inner cell mass. C) Tetraploid complementation.
Electrofusion of a two-cell stage embryo results in the generation of a single tetraploid cell.
Tetraploid cells continue to proliferate and develop normally up until the blastocyst stage,
but rarely contribute to embryonic structures. Therefore, aggregation of tetraploid and
diploid embryos results in lineage exclusivity, with tetraploid cells wholly contributing to
extraembryonic tissue. D) Injection of TS cells into the blastocoel. Injected TS cells
contribute exclusively to the trophectoderm. E) Viral infection of a blastocyst results in
transduction of the peripheral trophectoderm, whereas inner cells are shielded from viral
exposure. F) Intraplacental engraftment of cells or injection of virus to mature placentae,
resulting in regions of placenta that express foreign cellular proteins or are transduced with
virus, respectively.
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Table 1

Characterized gene promoters effective in targeting trophoblast lineages in vivo

NIH-PA Author Manuscript

Relevant promoter regions
necessary for trophoblastspecific expression

NIH-PA Author Manuscript

Gene

Function/Expression

Adenosine deaminase

Purine metabolizing enzyme;
expressed in all mouse trophoblast
subpopulations beginning at midgestation.

770-bp region situated 5.4 kb
upstream of transcription start site;
contains binding site for
trophoblast-specific element
binding protein.

[9,10]

CYP19

Aromatase complex; converts
androgens to estrogens; expressed
in human, but not mouse placenta.
The human promoter is active in
the mouse placenta.

501-bp 5′-flanking region of
placenta-specific Cyp19 exon I.1.

[30–32]

Eomesodermin

Regulation of trophoblast lineage
specification; expressed in TS cells
and early trophoblast cells,
primitive streak, telencephalon.

180-kb 5′-sequence on bacterial
artificial chromosome sufficient to
drive expression.

[25]

Growth hormone releasing hormone

Hypothalamic hormone that
stimulates release of growth
hormone; expressed by rodent
placenta; expression commences at
mid-gestation and continues
increasing until term.

7.5-kb-5′ flanking region and
sequences downstream to exon 1.

[24]

Human chorionic somato-mammotropin

Human growth hormone gene
cluster; expressed in human
syncytiotrophoblast at midgestation. No mouse homologue,
but transcriptionally active in mice.

Histone acetylation and
differential protein binding within
a remote locus control region 14–
32 kb upstream of gene cluster.

[27–29]

Placental lactogen II (PL-II; Prl3b1)

Member of expanded rodent
prolactin-like protein superfamily;
expressed by rodent trophoblast
giant cells and in mice,
spongiotrophoblast cells beginning
at mid-gestation.

2019 to 1340 bp upstream of
transcription start site; contains
elements for GATA, Ets, and
AP-2γ factor binding.

[12–14]

Renin

Involved in regulation of blood
volume and blood pressure;
expressed in fetal adrenal gland,
Wolffian duct, and trophoblast
giant cells during mid-late
pregnancy.

4-kb 5′-flanking region.

[23]

Tpbpa (4311)

Unknown function; expressed in
junctional zone trophoblast.

340-bp region situated 3740 bp
upstream of transcription start site.
Contains E-box binding elements
for basic helix-loop-helix
transcription factor binding.

[21,22]
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